GO:0046943 carboxylic acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046943 describes the molecular function of moving carboxylic acids (molecules with one or more carboxyl groups, COOH/COO-) across biological membranes.
• The monocarboxylate transporter (MCT/SLC16A) family is the best-characterized group of proteins carrying this activity, transporting lactate, pyruvate, and ketone bodies.
• GABA transporters (GAT1/SLC6A1) are carboxylic acid transporters whose function depends on specific charged amino acids in transmembrane helices.
• Sialic acid O-acetylation and Golgi transport intersect with carboxylic acid transporter activity through SLC33A1-dependent mechanisms.
• Altered carboxylic acid transport is linked to liver disease, neurological disorders, and metabolic reprogramming in cancer [1,7].
• CRISPR knockout, point-mutation, and knock-in models are essential to dissect the causal roles of individual transporters in disease [3,5].
Description
Carboxylic acid transmembrane transporter activity (GO:0046943) is a molecular function that enables the transfer of carboxylic acids from one side of a membrane to the other. Carboxylic acids are organic acids containing one or more carboxyl (COOH) groups or their anions (COO-). This activity is fundamental to cellular metabolism, neurotransmitter recycling, and drug disposition. The monocarboxylate transporter family (MCTs, SLC16A) represents the archetypal example, facilitating the proton-linked transport of lactate, pyruvate, and ketone bodies across plasma membranes. Beyond MCTs, GABA transporters (GATs) mediate the uptake of the inhibitory neurotransmitter gamma-aminobutyric acid, a carboxylic acid, and are critical for terminating synaptic transmission. The importance of this GO term extends to hepatic physiology, where gamma-aminobutyric acid transport influences liver function, and to microbial systems where benzoate transport supports aromatic acid degradation. Researchers studying metabolism, neurobiology, and cancer rely on precise characterization of these transporters to understand how cells maintain metabolic homeostasis and respond to environmental cues. The activity is also emerging as a target for therapeutic modulation, as exemplified by inhibitors of TMEM16A, a calcium-activated chloride channel that interacts with carboxylic acid transport pathways. Understanding the molecular details of carboxylic acid transmembrane transporter activity is therefore essential for both basic biology and translational medicine.
carboxylic acid transmembrane transporter activity At A Glance
| GO ID | GO:0046943 |
|---|---|
| GO term | carboxylic acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfer of carboxylic acids (e.g., lactate, pyruvate, GABA, benzoate) across membranes |
| Representative protein families | Monocarboxylate transporters (MCT/SLC16A), GABA transporters (GAT/SLC6A), SLC33A1 |
| Cellular locations | Plasma membrane, Golgi membrane, mitochondrial membrane |
| Associated processes | Metabolic homeostasis, neurotransmitter uptake, drug transport, sialic acid O-acetylation |
| Disease relevance | Liver disease, neurological disorders, cancer metabolism, metabolic acidosis |
What Is GO:0046943?
In our own words, GO:0046943 refers to the protein function that moves carboxylic acids, which are organic acids containing one or more carboxyl groups (COOH) or their dissociated anions (COO-), across a lipid bilayer membrane. This transfer can occur via facilitated diffusion, secondary active transport, or other mechanisms, and is essential for distributing these metabolites and signaling molecules between cellular compartments and across the plasma membrane.
Why Is carboxylic acid transmembrane transporter activity Important in Cell Biology?
Carboxylic acid transmembrane transporter activity is central to cellular energy metabolism, neurotransmitter recycling, and the absorption and distribution of numerous drugs and metabolites. Dysregulation of these transporters contributes to pathologies ranging from hepatic encephalopathy to epilepsy and cancer. For example, GABA transport in the liver modulates neurological outcomes in liver disease, while monocarboxylate transporters sustain the metabolic demands of proliferating cancer cells. Understanding this activity at the molecular level provides a foundation for developing targeted therapeutics and for interpreting genetic variants in transporter genes.
• Maintains cellular pH and metabolic balance by moving lactate and pyruvate across membranes.
• Terminates GABAergic signaling by clearing GABA from the synaptic cleft, preventing excitotoxicity.
• Supports liver function and ammonia detoxification through GABA transport in hepatocytes.
• Enables the uptake of aromatic carboxylic acids like benzoate in bacteria, relevant for bioremediation.
• Modulates sialic acid O-acetylation in the Golgi, affecting protein glycosylation and cell signaling.
• Contributes to drug resistance by transporting carboxylate-containing drugs out of cells.
• Plays a role in cancer metabolic reprogramming, where lactate transporters are often overexpressed.
• Provides targets for pharmacological intervention, such as TMEM16A inhibitors that affect carboxylic acid transport.
• Influences immune cell function through regulation of metabolite availability.
• Is essential for normal brain development and function, as mutations in GABA transporters cause neurological disorders.
Mechanism, Genes and Research Methods
What Happens During carboxylic acid transmembrane transporter activity?
In simple terms: The transporter grabs a carboxylic acid molecule on one side of the membrane and releases it on the other side.
The process begins with substrate recognition, where the transporter binds a carboxylic acid such as lactate, pyruvate, or GABA. For monocarboxylate transporters, binding is coupled to proton symport, allowing the co-transport of H+ and the monocarboxylate. GABA transporters utilize sodium and chloride gradients to drive uptake. The substrate is then translocated through a conformational change in the transporter protein, exposing it to the opposite side of the membrane. Finally, the substrate is released, and the transporter returns to its original conformation. This cycle is tightly regulated by substrate availability, membrane potential, and post-translational modifications [3,5].
Substrate specificity and recognition
In simple terms: Different transporters recognize different carboxylic acids based on their size, charge, and chemical structure.
Monocarboxylate transporters (MCTs) preferentially transport short-chain monocarboxylates like L-lactate, pyruvate, and ketone bodies, with specificity determined by a conserved arginine residue in the transmembrane domain. GABA transporters (GATs) are highly selective for GABA and related analogs, and mutagenesis studies have shown that only one of the charged amino acids in the transmembrane alpha-helices is essential for activity. Sialic acid O-acetylation in the Golgi involves SLC33A1-dependent transport of acetyl-CoA, a carboxylic acid derivative, highlighting the diversity of substrates. In bacteria, benzoate transporters recognize aromatic carboxylic acids, enabling degradation of environmental pollutants.
Energetics and driving forces
In simple terms: Some transporters use energy from ion gradients, while others simply let molecules flow down their concentration gradient.
MCTs typically function as proton symporters, using the transmembrane proton gradient to drive monocarboxylate transport. GABA transporters are sodium- and chloride-dependent, coupling GABA uptake to the inward sodium gradient. Some carboxylic acid transporters, such as those in the Golgi, may use antiport mechanisms. The energetics of transport are critical for maintaining cellular homeostasis, and disruption of ion gradients can lead to transporter dysfunction and disease [3,5].
Regulation of transporter activity
In simple terms: Cells can turn transporters on or off by modifying them or changing how many are on the cell surface.
Transporter activity is regulated at multiple levels, including gene expression, trafficking to the membrane, and post-translational modifications. For example, sialic acid can regulate GABA uptake activity of GAT1, as shown by altered transport kinetics upon changes in glycosylation. Phosphorylation and ubiquitination can control the surface expression of MCTs. In the liver, gamma-aminobutyric acid transport is influenced by hormonal and metabolic signals. These regulatory mechanisms ensure that carboxylic acid transport meets the dynamic needs of the cell.
Key Genes Involved in GO:0046943 carboxylic acid transmembrane transporter activity
The following genes encode proteins that exhibit carboxylic acid transmembrane transporter activity or are directly involved in its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A1 (MCT1) | Proton-linked monocarboxylate transporter for lactate, pyruvate, ketone bodies | Cancer metabolism, metabolic acidosis, drug transport |
| SLC16A3 (MCT4) | High-affinity lactate exporter | Hypoxia response, tumor microenvironment |
| SLC16A7 (MCT2) | Neuronal monocarboxylate transporter | Brain energy metabolism, neurodegeneration |
| SLC6A1 (GAT1) | Sodium- and chloride-dependent GABA transporter | Epilepsy, neurodevelopmental disorders |
| SLC6A13 (GAT2) | GABA and taurine transporter | Liver function, osmotic regulation |
| SLC33A1 | Acetyl-CoA transporter in Golgi | Sialic acid O-acetylation, CASD1 catalysis |
| TMEM16A (ANO1) | Calcium-activated chloride channel, interacts with carboxylic acid transport | Drug discovery, TMEM16A inhibitors |
| GABAT | GABA transaminase, metabolizes GABA | GABA homeostasis, liver disease |
| SLC25A1 | Mitochondrial citrate carrier | Metabolic reprogramming, cancer |
| SLC22A1 (OCT1) | Organic cation transporter, transports carboxylates | Drug disposition, liver function |
| SLC22A7 (OAT2) | Organic anion transporter | Hepatic clearance of carboxylic acids |
| MCT1 (SLC16A1) isoforms | Splice variants with altered kinetics | Tissue-specific metabolism |
| GAT3 (SLC6A11) | Astrocytic GABA transporter | Neurotransmitter recycling |
| SLC16A8 (MCT3) | Retinal pigment epithelium transporter | Vision, metabolic transport |
| SLC16A2 (MCT8) | Thyroid hormone transporter | Allan-Herndon-Dudley syndrome |
| SLC16A10 (MCT10) | Aromatic amino acid transporter | Thyroid hormone transport |
| SLC7A5 (LAT1) | Large neutral amino acid transporter | Cancer metabolism, mTOR signaling |
How Is carboxylic acid transmembrane transporter activity Regulated?
Carboxylic acid transmembrane transporter activity is regulated at transcriptional, translational, and post-translational levels. For instance, the expression of monocarboxylate transporters is induced by hypoxia and metabolic stress through HIF-1α and AMPK signaling. GABA transporter GAT1 is regulated by glycosylation, with sialic acid moieties modulating its uptake activity. In the liver, gamma-aminobutyric acid transport is influenced by hormonal signals and hepatic encephalopathy conditions. Additionally, SLC33A1-dependent acetyl-CoA transport affects Golgi sialic acid O-acetylation, linking carboxylic acid transport to glycosylation pathways. These regulatory mechanisms ensure that transport activity is matched to cellular demands.
carboxylic acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A1 (GAT1) | Epilepsy, neurodevelopmental disorders | Knockout mouse, patient-derived iPSCs |
| SLC16A1 (MCT1) | Cancer metabolism, lactic acidosis | Xenograft models, CRISPR knockout in cancer cell lines |
| SLC33A1 | Golgi sialic acid O-acetylation defects | Knock-in mice, CRISPR point mutations |
| TMEM16A (ANO1) | Cancer, cystic fibrosis | Overexpression and knockout models |
| SLC6A13 (GAT2) | Hepatic encephalopathy | Liver-specific knockout mice |
Carboxylic acid transporters in liver disease
Gamma-aminobutyric acid (GABA) transport in the liver plays a role in hepatic encephalopathy, a neuropsychiatric complication of liver failure. Studies have shown that GABA uptake activity is altered in liver disease, contributing to neurological symptoms. The liver expresses GABA transporters that clear GABA from circulation, and their dysfunction may exacerbate hyperammonemia-induced encephalopathy. Targeting these transporters could offer therapeutic strategies for managing hepatic encephalopathy.
Neurological disorders linked to GABA transport
Mutations in GABA transporter genes, particularly SLC6A1 (GAT1), are associated with epilepsy, autism spectrum disorder, and developmental delay. The transporter's activity depends on specific charged amino acids in transmembrane helices, and disruption of these residues abolishes transport. Sialic acid regulation of GAT1 further modulates its function, implicating glycosylation in neurological disease. Understanding these mechanisms is critical for developing precision therapies for GABA-related disorders.
Cancer metabolism and monocarboxylate transporters
Monocarboxylate transporters (MCTs) are often upregulated in cancer to support the Warburg effect, exporting lactate and maintaining intracellular pH. MCT1 and MCT4 are key players in tumor metabolic reprogramming and are associated with poor prognosis. Inhibitors of MCTs are being explored as anticancer agents. Additionally, TMEM16A inhibitors, which affect carboxylic acid transport, show promise in cancer and other diseases.
Sialic acid O-acetylation and Golgi transport defects
SLC33A1-dependent acetyl-CoA transport into the Golgi is required for sialic acid O-acetylation, a modification that affects cell surface interactions and signaling. Defects in this pathway can lead to altered glycosylation and have been linked to developmental disorders. The interplay between carboxylic acid transport and glycosylation highlights the broad impact of GO:0046943 on cellular physiology.
From carboxylic acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC16A1 impair lactate transport and tumor growth? | CRISPR knockout in cancer cell lines and mouse xenografts |
| What is the role of a specific charged residue in GAT1 function? | Point mutation knock-in in cell lines or mice |
| Can a disease-associated variant in SLC6A1 be corrected? | Knock-in of wild-type allele using CRISPR |
| Where is SLC33A1 localized and how does it affect Golgi function? | Tagged knock-in with fluorescent protein |
| Does overexpression of MCT4 enhance lactate export? | Overexpression in cell lines |
| What is the effect of TMEM16A inhibitors on carboxylic acid transport? | Pharmacological inhibition in knockout backgrounds |
How to Study the carboxylic acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transport rate of carboxylic acids | Kinetic analysis of MCTs and GATs [3,5] |
| CRISPR knockout | Loss-of-function effects on transport | Cancer metabolism, neurobiology [3,5] |
| Site-directed mutagenesis | Role of specific amino acids in transport | Structure-function studies of GAT1 |
| Fluorescence microscopy | Subcellular localization of transporters | Golgi transport of SLC33A1 |
| RNA-seq | Expression levels of transporter genes | Disease profiling, biomarker discovery |
| Proteomics | Protein abundance and modifications | Post-translational regulation of transporters |
| Metabolomics | Intracellular and extracellular metabolite levels | Metabolic flux analysis |
| CRISPR library screening | Identification of genes affecting transport | Discovery of novel regulators |
Genetic approaches to study carboxylic acid transporters
CRISPR-Cas9 knockout, point mutation, and knock-in models are powerful tools to dissect the function of carboxylic acid transporters. For example, knockout of SLC16A1 in cancer cells can reveal its role in lactate flux and proliferation. Point mutations in GAT1 transmembrane domains have identified essential residues for transport activity. Knock-in of tagged transporters allows visualization of subcellular localization and trafficking.
Biochemical and transport assays
Radiolabeled substrate uptake assays are the gold standard for measuring carboxylic acid transport activity. For instance, 14C-lactate or 3H-GABA uptake can be quantified in cells expressing wild-type or mutant transporters [3,5]. These assays can be coupled with ion substitution to determine driving forces. Additionally, mass spectrometry-based metabolomics can measure intracellular and extracellular metabolite levels to infer transport rates.
Imaging and localization studies
Fluorescence microscopy of tagged transporters (e.g., GFP-SLC33A1) enables real-time tracking of subcellular localization and dynamics. Super-resolution microscopy can resolve transporter clustering at the plasma membrane. For GABA transporters, immunohistochemistry has been used to map expression in brain and liver tissues [1,5].
Omics and bioinformatics
RNA-seq and proteomics can identify transporters differentially expressed in disease states. For example, transcriptomic profiling of liver disease models has revealed changes in GABA transporter expression. Bioinformatics analysis of transporter families, such as the MCT family, can predict substrate specificity and regulatory motifs. CRISPR library screening combined with metabolomics can uncover novel carboxylic acid transporters and their pathways.
How CRISPR Can Be Used to Study GO:0046943 carboxylic acid transmembrane transporter activity
Knockout
CRISPR knockout of carboxylic acid transporter genes, such as SLC16A1 or SLC6A1, allows researchers to study loss-of-function phenotypes. For example, SLC16A1 knockout in cancer cells reduces lactate uptake and impairs growth under hypoxia. Knockout of GAT1 in mice leads to elevated GABA levels and seizures, confirming its role in neurotransmitter clearance. These models are invaluable for validating transporter function in vivo.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to probe structure-function relationships. In GAT1, mutation of a single charged amino acid in the transmembrane domain abolishes transport activity, demonstrating its essential role. Similarly, point mutations in SLC33A1 can disrupt acetyl-CoA transport and Golgi sialic acid O-acetylation. These models help link specific residues to transport mechanisms and disease.
Knock-in
Knock-in of tagged or reporter genes enables visualization and tracking of transporters in their native context. For instance, knocking in a fluorescent tag on SLC33A1 allows live-cell imaging of Golgi dynamics. Knock-in of human disease variants into mouse models can recapitulate human phenotypes and test therapeutic interventions. This approach is particularly useful for studying transporter trafficking and regulation.
Overexpression
Overexpression of carboxylic acid transporters, such as MCT4, can enhance transport capacity and alter cellular metabolism. Overexpression of SLC16A3 in cancer cells increases lactate export and promotes acid resistance. Overexpression models are also used to study transporter regulation and to screen for inhibitors. Combined with CRISPR knockout, overexpression provides a complementary approach to dissect transporter biology.
How EDITGENE Supports carboxylic acid transmembrane transporter activity Research
Researchers studying carboxylic acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in a specific metabolic or neurological phenotype. This requires precise genetic models that can isolate the contribution of individual transporters from compensatory mechanisms. EDITGENE provides end-to-end CRISPR solutions to generate such models efficiently and reliably.
Contact EDITGENE today to design your custom CRISPR model for carboxylic acid transmembrane transporter activity research.
Frequently Asked Questions About carboxylic acid transmembrane transporter activity
What is carboxylic acid transmembrane transporter activity?
It is a molecular function (GO:0046943) that enables the transfer of carboxylic acids, such as lactate, pyruvate, and GABA, across biological membranes.
What genes are involved in carboxylic acid transmembrane transporter activity?
Key genes include SLC16A1 (MCT1), SLC16A3 (MCT4), SLC6A1 (GAT1), SLC6A13 (GAT2), and SLC33A1, among others [3,5,2].
How is carboxylic acid transport regulated?
It is regulated by gene expression, post-translational modifications, and ion gradients. For example, sialic acid modulates GAT1 activity, and hypoxia induces MCT expression.
What diseases are associated with carboxylic acid transporters?
Diseases include epilepsy, neurodevelopmental disorders, liver disease, and cancer, linked to mutations or dysregulation of transporters like GAT1 and MCTs [1,5,3].
What is the role of SLC16A1 in cancer?
SLC16A1 (MCT1) exports lactate and supports tumor growth under hypoxic conditions, making it a potential therapeutic target.
How can CRISPR be used to study carboxylic acid transporters?
CRISPR knockout, point mutation, and knock-in models allow researchers to dissect transporter function, validate disease variants, and test drug responses [3,5,2].
What is the function of GABA transporters?
GABA transporters (e.g., GAT1) clear the inhibitory neurotransmitter GABA from synapses, terminating signaling and preventing excitotoxicity.
What is the role of SLC33A1 in the Golgi?
SLC33A1 transports acetyl-CoA into the Golgi, which is required for sialic acid O-acetylation and proper glycosylation.
Are there inhibitors of carboxylic acid transporters?
Yes, inhibitors like TMEM16A blockers affect carboxylic acid transport and are being explored for cancer and other diseases.
How does sialic acid affect GABA transport?
Sialic acid modification of GAT1 regulates its uptake activity, linking glycosylation to neurotransmitter transport.
Conclusion
Carboxylic acid transmembrane transporter activity (GO:0046943) is a fundamental molecular function that underpins metabolic homeostasis, neurotransmission, and drug disposition. The diversity of transporters, from MCTs to GATs and SLC33A1, highlights the broad biological significance of this activity. Dysregulation of these transporters is implicated in liver disease, neurological disorders, and cancer, making them attractive therapeutic targets. Advances in CRISPR-based models and functional assays continue to unravel the mechanistic details and disease relevance of carboxylic acid transport. EDITGENE's comprehensive services empower researchers to generate precise genetic models and accelerate discoveries in this field.
References
- 1. Minuk GY. 1993. Gamma-aminobutyric acid and the liver.. Dig Dis 11(1):45-54 PMID: 8383020
- 2. Albers M et al.. 2026. Interplay of SLC33A1-dependent and -independent Golgi sialic acid O-acetylation in CASD1 catalysis.. Nat Commun 17(1) PMID: 41917001
- 3. Halestrap AP. 2012. The monocarboxylate transporter family--Structure and functional characterization.. IUBMB Life 64(1):1-9 PMID: 22131303
- 4. Truong EC et al.. 2017. Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A).. J Med Chem 60(11):4626-4635 PMID: 28493701
- 5. Pantanowitz S et al.. 1993. Only one of the charged amino acids located in the transmembrane alpha-helices of the gamma-aminobutyric acid transporter (subtype A) is essential for its activity.. J Biol Chem 268(5):3222-5 PMID: 8428999
- 7. Hu J et al.. 2011. Involvement of sialic acid in the regulation of γ--aminobutyric acid uptake activity of γ-aminobutyric acid transporter 1.. Glycobiology 21(3):329-39 PMID: 21045010
- 8. Choudhary A et al.. 2017. Benzoate transport in Pseudomonas putida CSV86.. FEMS Microbiol Lett 364(12) PMID: 28591829
